Antiepileptic drugs and risk of suicide: a nationwide study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Antiepileptic drugs and risk of suicide: a nationwide study. / Olesen, J.B.; Hansen, Peter Riis; Erdal, Jesper; Abildstrøm, Steen Zabell; Weeke, Peter; Fosbol, E.L.; Poulsen, Henrik Enghusen; Gislason, Gunnar H; Olesen, Jonas Bjerring; Fosbøl, Emil Loldrup.

In: Pharmacoepidemiology and Drug Safety, Vol. 19, No. 5, 2010, p. 518-24.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Olesen, JB, Hansen, PR, Erdal, J, Abildstrøm, SZ, Weeke, P, Fosbol, EL, Poulsen, HE, Gislason, GH, Olesen, JB & Fosbøl, EL 2010, 'Antiepileptic drugs and risk of suicide: a nationwide study', Pharmacoepidemiology and Drug Safety, vol. 19, no. 5, pp. 518-24. https://doi.org/10.1002/pds.1932

APA

Olesen, J. B., Hansen, P. R., Erdal, J., Abildstrøm, S. Z., Weeke, P., Fosbol, E. L., Poulsen, H. E., Gislason, G. H., Olesen, J. B., & Fosbøl, E. L. (2010). Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiology and Drug Safety, 19(5), 518-24. https://doi.org/10.1002/pds.1932

Vancouver

Olesen JB, Hansen PR, Erdal J, Abildstrøm SZ, Weeke P, Fosbol EL et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiology and Drug Safety. 2010;19(5):518-24. https://doi.org/10.1002/pds.1932

Author

Olesen, J.B. ; Hansen, Peter Riis ; Erdal, Jesper ; Abildstrøm, Steen Zabell ; Weeke, Peter ; Fosbol, E.L. ; Poulsen, Henrik Enghusen ; Gislason, Gunnar H ; Olesen, Jonas Bjerring ; Fosbøl, Emil Loldrup. / Antiepileptic drugs and risk of suicide: a nationwide study. In: Pharmacoepidemiology and Drug Safety. 2010 ; Vol. 19, No. 5. pp. 518-24.

Bibtex

@article{9fc03d1243c948dbb3ced90a944f96e5,
title = "Antiepileptic drugs and risk of suicide: a nationwide study",
abstract = "Purpose Patients with epilepsy or psychiatric diseases have increased risk of suicide, but whether the risk is influenced by antiepileptic drug (AED) treatment is unclear. Studies have suggested that AEDs in general increase the risk of suicidal behaviour shortly after initiation. This study investigated possible differences in suicide risk associated with different AEDs. Methods The use of AEDs in the Danish population from 1997 to 2006 was determined by prescription claims. The risk of suicide associated with use of AEDs was estimated by case-crossover analyses, where each case serves at its own control during different periods. For sensitivity, the risk of suicide was estimated by a time-dependent Cox proportional-hazard analysis in AED treatment-nave patients. Results There were 6780 cases committing suicide in the 10-year study period, of which 422 received AED treatment at the time of suicide. The case-crossover analysis estimated AED treatment initiation to increase the risk of suicide (odds ratio (OR): 1.84, 95% confidence interval (CI): 1.36-2.49). Clonazepam (OR: 2.01, CI: 1.25-3.25), valproate (OR: 2.08, CI: 1.01-4.16), lamotrigine (OR: 3.15, CI: 1.35-7.34) and phenobarbital (OR: 1.96, CI: 1.02-3.75) were associated with a significant increased risk, while the remaining examined AEDs did not significantly influence the risk. In the cohort comprising of 169 725 AED treatment-nave patients, the Cox proportional-hazard analysis yielded similar results. Conclusions This study suggests that clonazepam, valproate, lamotrigine and phenobarbital relatively shortly after treatment initiation may increase the risk of suicide. The increased risk of suicide associated with these AEDs appears to be a consistent finding. Copyright (C) 2010 John Wiley & Sons, Ltd",
author = "J.B. Olesen and Hansen, {Peter Riis} and Jesper Erdal and Abildstr{\o}m, {Steen Zabell} and Peter Weeke and E.L. Fosbol and Poulsen, {Henrik Enghusen} and Gislason, {Gunnar H} and Olesen, {Jonas Bjerring} and Fosb{\o}l, {Emil Loldrup}",
note = "(c) 2010 John Wiley & Sons, Ltd.",
year = "2010",
doi = "http://dx.doi.org/10.1002/pds.1932",
language = "English",
volume = "19",
pages = "518--24",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Antiepileptic drugs and risk of suicide: a nationwide study

AU - Olesen, J.B.

AU - Hansen, Peter Riis

AU - Erdal, Jesper

AU - Abildstrøm, Steen Zabell

AU - Weeke, Peter

AU - Fosbol, E.L.

AU - Poulsen, Henrik Enghusen

AU - Gislason, Gunnar H

AU - Olesen, Jonas Bjerring

AU - Fosbøl, Emil Loldrup

N1 - (c) 2010 John Wiley & Sons, Ltd.

PY - 2010

Y1 - 2010

N2 - Purpose Patients with epilepsy or psychiatric diseases have increased risk of suicide, but whether the risk is influenced by antiepileptic drug (AED) treatment is unclear. Studies have suggested that AEDs in general increase the risk of suicidal behaviour shortly after initiation. This study investigated possible differences in suicide risk associated with different AEDs. Methods The use of AEDs in the Danish population from 1997 to 2006 was determined by prescription claims. The risk of suicide associated with use of AEDs was estimated by case-crossover analyses, where each case serves at its own control during different periods. For sensitivity, the risk of suicide was estimated by a time-dependent Cox proportional-hazard analysis in AED treatment-nave patients. Results There were 6780 cases committing suicide in the 10-year study period, of which 422 received AED treatment at the time of suicide. The case-crossover analysis estimated AED treatment initiation to increase the risk of suicide (odds ratio (OR): 1.84, 95% confidence interval (CI): 1.36-2.49). Clonazepam (OR: 2.01, CI: 1.25-3.25), valproate (OR: 2.08, CI: 1.01-4.16), lamotrigine (OR: 3.15, CI: 1.35-7.34) and phenobarbital (OR: 1.96, CI: 1.02-3.75) were associated with a significant increased risk, while the remaining examined AEDs did not significantly influence the risk. In the cohort comprising of 169 725 AED treatment-nave patients, the Cox proportional-hazard analysis yielded similar results. Conclusions This study suggests that clonazepam, valproate, lamotrigine and phenobarbital relatively shortly after treatment initiation may increase the risk of suicide. The increased risk of suicide associated with these AEDs appears to be a consistent finding. Copyright (C) 2010 John Wiley & Sons, Ltd

AB - Purpose Patients with epilepsy or psychiatric diseases have increased risk of suicide, but whether the risk is influenced by antiepileptic drug (AED) treatment is unclear. Studies have suggested that AEDs in general increase the risk of suicidal behaviour shortly after initiation. This study investigated possible differences in suicide risk associated with different AEDs. Methods The use of AEDs in the Danish population from 1997 to 2006 was determined by prescription claims. The risk of suicide associated with use of AEDs was estimated by case-crossover analyses, where each case serves at its own control during different periods. For sensitivity, the risk of suicide was estimated by a time-dependent Cox proportional-hazard analysis in AED treatment-nave patients. Results There were 6780 cases committing suicide in the 10-year study period, of which 422 received AED treatment at the time of suicide. The case-crossover analysis estimated AED treatment initiation to increase the risk of suicide (odds ratio (OR): 1.84, 95% confidence interval (CI): 1.36-2.49). Clonazepam (OR: 2.01, CI: 1.25-3.25), valproate (OR: 2.08, CI: 1.01-4.16), lamotrigine (OR: 3.15, CI: 1.35-7.34) and phenobarbital (OR: 1.96, CI: 1.02-3.75) were associated with a significant increased risk, while the remaining examined AEDs did not significantly influence the risk. In the cohort comprising of 169 725 AED treatment-nave patients, the Cox proportional-hazard analysis yielded similar results. Conclusions This study suggests that clonazepam, valproate, lamotrigine and phenobarbital relatively shortly after treatment initiation may increase the risk of suicide. The increased risk of suicide associated with these AEDs appears to be a consistent finding. Copyright (C) 2010 John Wiley & Sons, Ltd

U2 - http://dx.doi.org/10.1002/pds.1932

DO - http://dx.doi.org/10.1002/pds.1932

M3 - Journal article

VL - 19

SP - 518

EP - 524

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -

ID: 34076981